During a review of 2015 and 2016 claims processing of DEA schedule II (CII) prescription drug claims, PerformRx noticed an increase in the number of schedule II (CII) drugs being incorrectly billed as refills at the point of sale (POS). While this may have been due to an error in entering and submitting prescription claim information to PerformRx, efforts need to continually be made to prevent these types of errors as they can signal potential fraud, waste or abuse incorrectly. Pursuant to 21 U.S.C. § 829(a), refills of medications with a DEA schedule II (CII) designation are prohibited at POS.